Clinical trial • Phase III • Immunology

GLPG3667 for Autoimmune disorder | Inflammatory diseases

Phase III trial of GLPG3667 for Autoimmune disorder | Inflammatory diseases. 16 participants.

Overview

Trial Therapeutic Area
Immunology
Trial Disease
Autoimmune disorder | Inflammatory diseases
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
23-03-2026
First CTIS Authorization Date
27-04-2026

Trial design

Phase III trial across 1 site in Belgium.

Target Sample Size
16

Eligibility

Recruits 16 isVulnerablePopulationSelected = true in trial record; no further details on vulnerable population types, consent or assent handling provided.

Vulnerable Population
isVulnerablePopulationSelected = true in trial record; no further details on vulnerable population types, consent or assent handling provided

Recruitment

Planned Sample Size
16
Recruitment Window Months
3

Geography

Total Number Of Sites
1
Total Number Of Participants
16

Belgium

Earliest CTIS Part Ii Submission Date
15-04-2026
Latest Decision Or Authorization Date
27-04-2026
Processing Time Days
12
Number Of Sites
1
Number Of Participants
16

Sites

Site Name
SGS Belgium - Drie Eikenstraat 655
Department Name
SGS-Clinical Research CPU
Contact Person Name
Lotte Verwilligen
Contact Person Email
Lotte.Verwilligen@sgs.com
Number Of Participants
16

Sponsor

Primary sponsor

Full Name
Galapagos
Organisation Type
Pharmaceutical company
Country Of Registered Address
Belgium

Investigational products

Investigational Product Name
GLPG3667

Related trials

Other published trials that may interest you.